1. bookVolume 75 (2021): Issue 3 (June 2021)
Journal Details
License
Format
Journal
First Published
14 Sep 2008
Publication timeframe
6 times per year
Languages
English
access type Open Access

Immunopathogenic Treatment Options for Psoriasis Patients Under a Restrictive Reimbursement Environment

Published Online: 22 Jul 2021
Page range: 158 - 166
Received: 11 Jun 2020
Accepted: 01 Mar 2021
Journal Details
License
Format
Journal
First Published
14 Sep 2008
Publication timeframe
6 times per year
Languages
English
Abstract

This article is aimed to provide an overview of psoriasis clinical aspects, available treatment options for moderate-to-severe psoriasis in Baltics and summarises recommendations of authors for use of different biologicals in psoriasis patients under a limited reimbursement environment.

Keywords

Benezeder, T., Wolf, P. (2019). Resolution of plaque-type psoriasis: What is left behind (and reinitiates the disease). Springer Semin. Immunopathol, 32 (6), 1–12. Search in Google Scholar

Boehncke, W. H., Boehncke, S. (2014). More than skin-deep: The many dimensions of the psoriatic disease. Swiss Med. Wkly., 144 (171), 68–75. Search in Google Scholar

Boniface, K., Jacquemin, C., Darrigade, A. S., Dessarthe, B., Martins C., Boukhedouni, N. (2018). Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3. J. Invest. Dermatol., 138 (2), 355–364. Search in Google Scholar

Cather, J. C., Crowley, J. J. (2014). Use of biologic agents in combination with other therapies for the treatment of psoriasis. Amer. J. Clin. Dermatol., 15 (6), 467–478. Search in Google Scholar

Chiricozzi, A., Romanelli,. P., Volpe, E., Borsellino, G., Romanelli, M. (2018). Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci., 19 (1), 179–185 Search in Google Scholar

Christophers, E. (2001) Psoriasis — epidemiology and clinical spectrum. Clin. Exp. Dermatol., 26 (4), 314–320. Search in Google Scholar

Christophers, E., van de Kerkhof, P. C. (2019). Severity, heterogeneity and systemic inflammation in psoriasis. J. Eur. Acad. Dermatol. Venereol., 33 (4), 643–647. Search in Google Scholar

Cosentyx 150 mg powder for solution for injection. SmPC. https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf (accessed 15 March 2020). Search in Google Scholar

Danese, S., Vermeire, S., D’Haens, G., Panés J., Dignass, A., Magro F. (2020). DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial. J. Crohns Colitis, 14 (1), 49–52. Search in Google Scholar

Dubertret, L., Mrowietz, U., Rank., A, Van De Kerkhof, P. C., Chimenti, S., Lotti, T. (2006). EUROPSO patient survey. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Brit. J. Dermatol., 155 (4), 729–736. Search in Google Scholar

Eder, L., Haddad, A., Rosen C. F., Lee K. A., Chandran V., Cook, R. (2016). The incidence and risk factors for psoriatic arthritis in patients with psoriasis: A prospective cohort study. Arthritis Rheum., 68 (4), 915–923. Search in Google Scholar

Enbrel 25 mg solution for injection in pre-filled syringe Enbrel 50 mg solution for injection in pre-filled syringe. SmPC. https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf on 10/03/2020 (accessed 01.03.2020). Search in Google Scholar

From evolution to revolution: IL-23 in the treatment of psoriasis patients. EMJ Dermatol., 6, 71–78. https://www.emjreviews.com/dermatology/symposium/from-evolution-to-revolution-il-23-in-the-treatment-of-psoriasis-patients (accessed 01.03.2020). Search in Google Scholar

Gaies, E., Jebabli, N., Trabelsi, S., Salouage, I., Charfi, R., Lakhal, M. (2012). Methotrexate side effects: Review article. J. Drug Metab. Toxicol., 3 (4), 1–5. Search in Google Scholar

Gisondi, P., Del Giglio, M., Girolomoni, G. (2017). Treatment approaches to moderate to severe psoriasis. Int. J. Mol., 18 (11), 2427–2429. Search in Google Scholar

Global Psoriasis Atlas. https://globalpsoriasisatlas.org/statistics (accessed 20.04.2020). Search in Google Scholar

Gooderham, M. J., Papp, K. A., Lynd, C.W. (2018). Shifting the focus–the primary role of IL-23 in psoriasis and other inflammatory disorders. J. Eur. Acad. Dermatol. Venereol., 32 (7), 1111–1119. Search in Google Scholar

Griffiths, C. E., Barker, J. N. (2007). Pathogenesis and clinical features of psoriasis. The Lancet, 370, 263–271. Search in Google Scholar

Hao, J. Q. (2014). Targeting interleukin-22 in psoriasis. Inflammation, 37 (1), 94–99. Search in Google Scholar

Hartmane, I., Mikažāns, I., Ivdra,. I, Dērveniece, A., Ančupāne, I. (2016). Experience of phototherapy in dermatological praxis in complex therapy of psoriasis patients. Proc. Latv. Acad. Sci. Section B, 70 (1), 7–12. Search in Google Scholar

Humira 40 mg solution for injection in pre-filled syringe Humira 40 mg solution for injection in pre-filled pen. SmPC. Last revised 08/09/2008. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf (accessed 15.03.2020). Search in Google Scholar

Ilumetri 100 mg solution for injection in pre-filled syringe. SmPC. Last revised 17/09/2018. https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf on 10/03/2020 (accessed 15.03.2020). Search in Google Scholar

Jain, S., Kaur, I. R., Das, S., Bhattacharya, S. N. Singh, A. (2009) T helper 1 to T helper 2 shift in cytokine expression: An autoregulatory process in superantigen-associated psoriasis progression? J. Med. Microbiol., 58 (2), 180–184. Search in Google Scholar

Kerdel, F., Zaiac, M. (2015). An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol. Ther., 28 (6), 390–403. Search in Google Scholar

Kyntheum 210 mg solution for injection in pre-filled syringe. SmPC. Last revised 17/07/2017. https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf (accessed 15.03. 2020). Search in Google Scholar

Li, K., Joshua, F. R., Marano, C., Zhang, H., Yang, F., Feagan, B. G. (2019). Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in Ulcerative Colitis. Z. Gastroenterol., 57 (5), 169–187. Search in Google Scholar

Mahil, S. K., Capon, F., Barker J. N. (2016). Update on psoriasis immuno-pathogenesis and targeted immunotherapy. Springer Semin. Immunopathol., 38 (1), 11–27. Search in Google Scholar

Malik, B. T., Byrne, K. T., Vella, J. L., Zhang, P., Shabaneh, T. B., Steinberg, S. M. (2017). Resident memory T cells in skin mediate durable immunity to melanoma. Sci. Immunol., 2 (10), 35–47. Search in Google Scholar

Marti, D. A.,Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G. (2013). The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. J. Invest Dermatol., 133 (1), 17–26. Search in Google Scholar

Matos, T. R., O’Malley, J. T., Lowry, E. L., Hamm, D., Kirsch I. R. (2017). Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αā T cell clones. J. Clin. Invest., 127 (11), 4031–4041. Search in Google Scholar

Mattozzi, C., Salvi M., D’epiro, S., Giancristoforo, S., Macaluso, L., Luci, C. (2013). Importance of regulatory T cells in the pathogenesis of psoriasis. Dermatology, 227 (2), 134–145. Search in Google Scholar

Medicines to be reimbursed. Nacionālais Veselības Dienests [National Health Service]. http://www.vmnvd.gov.lv/en/cross-border-healthcare-contact-point/health-care-in-latvia/medicines-to-be-reimbursed on 06/04/2020 (accessed 15.04. 2020). Search in Google Scholar

Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B. (2011). Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J. Amer. Acad. Dermatol., 65 (1), 137–174. Search in Google Scholar

Ministry of Health of the Republic of Lithuania. http://sam.lrv.lt/en/ (accessed 15.04.2020). Search in Google Scholar

Möller, A. H, Erntoft, S., Vinding, G. R., Jemec G. B. (2015). A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat. Outcome Meas., 6, 167–177. Search in Google Scholar

Monteleone, G., Pallone F., MacDonald, T. T., Chimenti, S., Costanz, A. (2011). Psoriasis: From pathogenesis to novel therapeutic approaches. Clin. Sci., 120 (1), 8–12. Search in Google Scholar

Mrowietz, U., De Jong, E. M., Kragballe, K., Langley, R., Nast, A., Puig, L. (2014). A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol., 28 (4), 438–453. Search in Google Scholar

Mrowietz, U., Kragballe, K., Reich, K., Spul, P., Griffiths. C. E., Nast, A. (2011). Definition of treatment goals for moderate to severe psoriasis:A European consensus. Arch. Dermatol. Res., 303 (1), 1–10. Search in Google Scholar

Nast, A., Boehncke, W. H., Mrowietz, U., Ockenfels, H. M., Philipp, S., Reich, K. (2012). S3–Guidelines on the treatment of psoriasis vulgaris (English version). Update. J. Dtsch. Dermatol. Ges., 10, 1–95. Search in Google Scholar

Order for the approval of the procedure for the treatment of psoriasis with medicinal products the purchase of which is covered by the compulsory health insurance fund’s budget. Ministry of Health of Republic of Lithuania. https://www.e-tar.lt/portal/en/legalAct/c51f3b408d8311e7a3c4a5eb10f04386/nHZdKhSspS on 06/04/2020 (accessed 15.04.2020) (in Lithuanian). Search in Google Scholar

Owczarczyk-Saczonek, A., Czerwińska, J., Placek, W. (2018). The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. Acta Dermatovenerol. Alp. Pannonica Adriat., 27 (1), 17–23. Search in Google Scholar

Parisi, R., Symmons, D. P, Griffiths, C. E, Ashcrof, D. M.(2013). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol.., 133 (2), 377–385. Search in Google Scholar

Qu, N., Xu, M., Mizoguchi, I., Furusawa, J. I., Kaneko, K., Watanabe, K. (2013). Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin. Dev. Immunol., 34 (16), 231–235. Search in Google Scholar

Rahman, P., Elder, J. T. (2005). Genetic epidemiology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 64 (2), 37–49. Search in Google Scholar

Rahman, P., Siannis, F., Butt, C., Farewell, V., Peddle, L., Pellett, F (2006). TNFα polymorphisms and risk of psoriatic arthritis. Ann. Rheum. Dis., 65 (7), 919–923. Search in Google Scholar

Reich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S (2019). Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial. The Lancet, 394 (1 0201), 831–839. Search in Google Scholar

Reich, K. (2012). The concept of psoriasis as a systemic inflammation: Implications for disease management. J. Eur. Acad. Dermatol. Venereol., 26, 3–11. Search in Google Scholar

Reich, K., Burden, A. D., Eaton, J. N., Hawkins, N. S. (2012). Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials. Brit. J. Dermatol., 166 (1), 179–188. Search in Google Scholar

Reich, K., Nestle, F. O., Papp, K., Ortonne, J. P., Evans, R, Guzzo, C., Li, S., Dooley, L. T., Griffiths, C. E., (2005). EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. The Lancet, 366 (9494), 1367–1374. Search in Google Scholar

Reimbursemen drug list. Nacionālais Veselības Dienests [National Health Service]. http://www.vmnvd.gov.lv/lv/kompensejamie-medikamenti/kompensejamo-zalu-saraksts from 06/04/2020 (accessed 15.04. 2020). Search in Google Scholar

Remsima 100 mg powder for concentrate for solution for infusion. SmPC. Last revised 21/06/2018. https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf (accessed 15.04. 2020). Search in Google Scholar

Rendon, A, Schäkel, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20 (6), 1475. Search in Google Scholar

Signorovitch, J. E., Betts, K.A., Yan, Y. S., LeReun, C., Sundaram, M., Wu, E. Q., Mulani, P. (2015). Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response. Brit. J. Dermatol., 172 (2), 504–512. Search in Google Scholar

Skyrizi 75 mg solution for injection in pre-filled syringe. SmPC. Last revised 26/04/2019. https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf (accessed 15.04.2020). Search in Google Scholar

STELARA 45 mg solution for injection STELARA 90 mg solution for injection STELARA 45 mg solution for injection in pre-filled syringe STELARA 90 mg solution for injection in pre-filled syringe. SmPC. Last revised 19/09/2013. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf (accessed 15.04.2020). Search in Google Scholar

Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie A., Van Voorhees A. S. (2017). Psoriasis and comorbid diseases: Epidemiology. J. Amer. Acad. Dermatol.. 76 (3), 377–390. Search in Google Scholar

Taltz 80 mg solution for injection in pre-filled syringe. SmPC. Last revised 25/04/2016. https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf (accessed 15.04. 2020). Search in Google Scholar

Tervishoiuteenuste loetelu. https://www.haigekassa.ee/partnerile/raviasutusele/tervishoiuteenuste-loetelu on 06/04/2020 (accessed 15.04.2020). Search in Google Scholar

Tremfya 100 mg solution for injection in pre-filled syringe. Tremfya 100 mg solution for injection in pre-filled pen. SmPC. Last revised 10/11/2017. https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf (accessed 15.04. 2020). Search in Google Scholar

Use of public budget resources to pay national reimburses [Valsts budžeta līdzekļu izlietojums valsts kompensējamo zāļu apmaksā]. Nacionālais Veselības Dienests [National Health Service]. http://vmnvd.gov.lv/lv/ligumpartneriem/operativa-budzeta-informacija/valsts-budzeta-lidzeklu-izlietojums-valsts-kompensejamo-zalu-apmaksa on 07/04/2020 (accessed 15.04.2020). Search in Google Scholar

Vide, J., Magina S, (2017). Moderate to severe psoriasis treatment challenges through the era of biological drugs. An. Bras. Dermatol., 92 (5), 668–674. Search in Google Scholar

Wada, Y., Cardinale, I., Khatcherian, A., Chu, J., Kantor, A. B., Gottlieb, A.B. (2012). Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PloS One, 7 (4), 1371–1380. Search in Google Scholar

Watanabe, R. (2019). Protective and pathogenic roles of resident memory T cells in human skin disorders. J. Dermatol. Sci., 31 (5), 151–157. Search in Google Scholar

Yeung, H., Takeshita, J., Mehta, N. N., Kimmel, S. E., Ogdie, A., Margolis, D. J., Shin, D. B., Attor, R., Troxel, A. B., Gelfand, J. M. (2013). Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatol., 149 (10), 1173–1179. Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo